Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Our Science

> Our Science

> Poster and Presentation

Poster and Presentation

Peer Reviewed Publications

Clinical Proof of Concept (POC) of A Novel Dual-acting Glucokinase Activator (GKA) Achieved: HMS5552 improved glycemic control in T2DM Patients

2017 June

Hua Medicine

Jun 09, 2017

4706

Online link unavailable, presentation available upon request. (BD@ceer-cn.com)

Return list

Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator, Dorzagliatin (HMS5552) 12 Weeks Treatment in T2D Patients in China

Clinical Proof of Concept (POC) of Glucokinase Activator HMS5552 Achieved in Chinese T2DM Patients: HbA1c Reduction of 1.22% with 100% Response Rate and Improved β-cell Function

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.